BioRestorative raises $8.1M via warrant exercise and new private placement warrants

BioRestorative Therapies, Inc.

Gross proceeds of $8.1M from exercise of existing warrants for 3,351,580 shares at $2.33/share.
New warrants issued for up to 2,513,685 shares at $2.43/share, 5-year term, in a private placement.
Proceeds to fund BRTX-100 clinical trials, metabolic ThermoStem R&D, and working capital.
Roth Capital Partners served as financial advisor; fee approx. $528,000.
Existing warrant shares already registered; resale registration for new warrants to be filed within 10 days.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

BioRestorative Therapies, Inc. entered into Agreements with certain holders of its existing warrants valued at approximately $8.1 million (effective 2024-02-06).

Action: entry
Agreement: atm program
Counterparty: certain holders of its existing warrants
Value: approximately $8.1 million
Effective: 2024-02-06

Exact text from the filing

On February 6, 2024, BioRestorative Therapies, Inc. (the “Company”) entered into agreements (the “Agreements”) with certain holders of its existing warrants exercisable for an aggregate of 3,351,580 shares of its common stock (collectively, the “Existing Warrants”), to exercise their warrants at a reduced exercise price of $2.33 per share, in exchange for new warrants (the “New Warrants”) as described below.

View on SEC.gov

38 material agreements filed in the last 30 days. Browse all material agreements →

BioRestorative Therapies, Inc. filing history →

Source: SEC EDGAR

accession 0001021771-24-000033

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.